Can't sleep on retatrutide? You're not alone in noticing changes to your sleep during treatment. Retatrutide is an investigational triple receptor agonist — acting on GLP-1, GIP, and glucagon receptors — currently available only through authorised clinical trials for obesity and type 2 diabetes. Sleep disturbances, including difficulty falling or staying asleep, have been reported by some trial participants, though a confirmed causal link has not yet been established. This article explores why retatrutide may affect sleep, how common insomnia is, practical management strategies, and when to seek medical advice.

Why Retatrutide May Affect Your Sleep

Retatrutide's GLP-1 receptor activity may interact with central nervous system arousal pathways, and gastrointestinal side effects such as nausea can indirectly disrupt sleep, though no direct causal mechanism has been confirmed.

Retatrutide is an investigational triple receptor agonist currently in clinical trials for obesity and type 2 diabetes. It acts on three receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and is only available to patients enrolled in authorised clinical trials.

The GLP-1 receptor system is known to interact with central nervous system pathways involved in appetite regulation and arousal. It has been hypothesised — though not yet confirmed in clinical studies — that activation of these pathways may influence neurotransmitter activity in ways that could affect sleep. Some participants in clinical trials have reported difficulty falling or staying asleep, particularly in the early weeks of treatment, though whether this reflects a direct drug effect remains uncertain.

Retatrutide's glucagon receptor activity increases energy expenditure and metabolic rate. Whether this contributes to sleep difficulties in humans is not established; this remains a plausible hypothesis rather than a confirmed mechanism.

Nausea and gastrointestinal discomfort — the most commonly reported side effects of this drug class — can also indirectly disrupt sleep by causing physical unease at night. Because retatrutide is still in clinical development, the full profile of its effects on sleep continues to be characterised, and any causal relationship between the drug and insomnia has not yet been formally established.

How Common Is Insomnia With This Medication?

Insomnia was not among the most prominently reported adverse events in published phase 2 retatrutide trial data; obesity itself is a major contributor to poor sleep and may account for some reported disturbances.

Because retatrutide remains in the clinical trial phase, comprehensive real-world data on the prevalence of sleep disturbances are not yet available. Published phase 2 trial data (Jastreboff et al., NEJM, 2023) reported on adverse events in participants receiving retatrutide for obesity; gastrointestinal side effects — including nausea, vomiting, and diarrhoea — were the most frequently documented. Insomnia was not among the most prominently reported adverse events in that dataset, though the full adverse event profile across all ongoing trials continues to be collected and assessed.

For context, sleep disturbances have been reported with other approved GLP-1 receptor agonists. The UK Summary of Product Characteristics (SmPC) for liraglutide 3 mg (Saxenda) lists insomnia as a common adverse reaction. By contrast, the SmPCs for semaglutide (Wegovy and Ozempic) do not list insomnia as a common adverse effect. Given that retatrutide shares GLP-1 receptor activity with these agents, occasional sleep disruption is plausible, but no confirmed causal link has been established for retatrutide specifically.

It is also important to consider that obesity itself — the primary condition retatrutide is being developed to treat — is strongly associated with poor sleep quality, obstructive sleep apnoea (OSA), and insomnia. Some sleep difficulties reported during trials may therefore reflect the underlying condition rather than a direct drug effect. As weight loss progresses, sleep quality may improve for many participants, particularly those with obesity-related OSA, though this relationship requires careful clinical assessment on an individual basis. Distinguishing between drug-induced and disease-related sleep changes can be challenging and warrants ongoing monitoring by the trial team.

Managing Sleep Difficulties During Treatment

NICE-recommended sleep hygiene measures and CBT-I are the first-line approaches for insomnia; any changes to dose timing or use of sleep aids must be agreed with your trial team before implementation.

If you are participating in a retatrutide clinical trial and are having difficulty sleeping, there are several practical strategies that may help. Always discuss any changes to your routine with your trial team before making adjustments, and do not start any over-the-counter sleep aids, herbal remedies, or supplements without first consulting your trial team or GP, as these may interact with your trial medication or affect trial data.

Timing of your dose: It may be worth discussing with your trial team whether the timing of your injection could be adjusted. Some patients find that taking their dose earlier in the day is helpful, though there is no established clinical evidence that retatrutide has a direct stimulatory effect on sleep; any adjustment should be agreed with your trial team rather than made independently.

Sleep hygiene measures are a well-evidenced, first-line approach recommended by NICE for insomnia (NICE guideline NG215). These include:

• Maintaining a consistent sleep and wake time, even at weekends

• Avoiding caffeine, alcohol, and heavy meals in the hours before bed

• Keeping the bedroom cool, dark, and quiet

• Limiting screen exposure (phones, tablets, televisions) for at least one hour before sleep

• Engaging in relaxing activities such as reading or gentle stretching in the evening

Further self-care advice is available on the NHS website (nhs.uk/insomnia).

Cognitive Behavioural Therapy for Insomnia (CBT-I) is the recommended first-line treatment for persistent insomnia according to NICE guidance (NG215). It is available via NHS Talking Therapies and through NICE-recommended digital CBT-I programmes (availability may vary by area — your GP can advise on local options). This approach addresses the thoughts and behaviours that perpetuate poor sleep and is suitable alongside ongoing medication.

If nausea is contributing to your sleep difficulties, eating smaller, lower-fat meals and avoiding lying down immediately after eating may help reduce overnight discomfort. Staying well hydrated throughout the day — rather than drinking large amounts close to bedtime — can also be beneficial.

When to Speak to Your GP or Trial Team

Contact your trial team or GP promptly if insomnia persists beyond three to four weeks, or if you develop palpitations, signs of sleep apnoea, or severe abdominal pain.

Because retatrutide is only available through clinical trials, your first point of contact for any side effects — including sleep disturbances — should be your trial investigator or the clinical team overseeing your participation. They are best placed to assess whether your symptoms are related to the medication, adjust your dose if appropriate, or determine whether you should continue in the trial.

There are specific circumstances in which you should seek prompt medical advice, either from your trial team or your GP:

• Persistent insomnia lasting more than three to four weeks that is significantly affecting your daytime functioning, mood, or concentration

• Symptoms of anxiety or low mood that have developed or worsened since starting treatment, as these can both cause and be exacerbated by poor sleep

• Signs of obstructive sleep apnoea — such as loud snoring, gasping during sleep (reported by a partner), or excessive daytime sleepiness — which require formal assessment and may need referral to a sleep clinic

• New or worsening palpitations or an irregular heartbeat at night — GLP-1-based medicines can be associated with a modest increase in resting heart rate; any new palpitations should be assessed promptly by a clinician

• Severe or persistent upper abdominal pain, particularly if it radiates to the back and is accompanied by vomiting — this may indicate pancreatitis or a gallbladder problem and requires prompt medical review

• Severe or worsening nausea, vomiting, or diarrhoea that is preventing adequate nutrition or hydration, as this may lead to dehydration and, in some cases, acute kidney injury; contact your trial team or GP promptly if you are unable to keep fluids down

When to seek urgent help: Call 999 or go to your nearest A&E immediately if you experience chest pain, severe breathlessness, collapse, or signs of a severe allergic reaction. Call NHS 111 for urgent medical advice that cannot wait for a GP appointment.

Your GP can also provide access to NHS sleep services, refer you for CBT-I, or investigate other underlying causes of insomnia unrelated to your medication. Open communication between your GP and trial team is important to ensure your overall care is coordinated safely.

Other Side Effects to Be Aware Of

The most common retatrutide side effects are gastrointestinal, including nausea, vomiting, and diarrhoea; other notable risks include dehydration, modest heart rate increases, hypoglycaemia, and gallbladder problems.

Beyond sleep disturbances, retatrutide carries a side effect profile broadly consistent with other agents in the incretin-based drug class. Based on published phase 2 clinical trial data, the most commonly reported adverse effects include:

• Gastrointestinal effects: Nausea, vomiting, diarrhoea, constipation, and reduced appetite are the most frequently reported side effects. These tend to be most prominent during dose escalation and often improve over time as the body adapts.

• Dehydration and kidney effects: Persistent vomiting or diarrhoea can lead to dehydration, which in some cases may affect kidney function. Contact your trial team or GP promptly if you are unable to maintain adequate fluid intake.

• Injection site reactions: Mild redness, bruising, or discomfort at the injection site can occur, as with other subcutaneous injectable medications.

• Hypoglycaemia: Whilst the risk is lower than with insulin or sulphonylureas, low blood glucose can occur, particularly in individuals also taking other glucose-lowering agents.

• Heart rate changes: GLP-1 receptor agonists are associated with a modest increase in resting heart rate. This may be relevant for individuals with pre-existing cardiac conditions and should be discussed with your trial team.

• Gallbladder problems: GLP-1 receptor agonists and rapid weight loss are associated with an increased risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). Seek prompt medical advice if you develop severe abdominal pain, particularly in the upper right abdomen.

Regarding thyroid effects: animal studies with GLP-1 receptor agonists have identified C-cell changes in rodents, but the clinical relevance of these findings in humans has not been established. This is not considered a confirmed risk in people, though participants with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia should ensure this has been disclosed to their trial team.

As retatrutide has not yet received MHRA or EMA approval, it does not currently have a published SmPC. All safety monitoring occurs within the structured framework of the clinical trial, and any concerns should be reported through the trial's adverse event reporting process without delay.

In addition to trial reporting, patients are encouraged to report any suspected side effects directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. This helps the MHRA monitor the safety of medicines and medical devices used in the UK.

Frequently Asked Questions